MX2021007394A - Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a. - Google Patents

Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.

Info

Publication number
MX2021007394A
MX2021007394A MX2021007394A MX2021007394A MX2021007394A MX 2021007394 A MX2021007394 A MX 2021007394A MX 2021007394 A MX2021007394 A MX 2021007394A MX 2021007394 A MX2021007394 A MX 2021007394A MX 2021007394 A MX2021007394 A MX 2021007394A
Authority
MX
Mexico
Prior art keywords
methods
gdf8
activin
compositions
leptin receptor
Prior art date
Application number
MX2021007394A
Other languages
English (en)
Spanish (es)
Inventor
Judith ALTAREJOS
Jesper Gromada
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2021007394A publication Critical patent/MX2021007394A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2021007394A 2018-12-18 2019-12-17 Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a. MX2021007394A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862781226P 2018-12-18 2018-12-18
PCT/US2019/066908 WO2020131910A1 (en) 2018-12-18 2019-12-17 Compositions and methods for enhancing body weight and lean muscle mass using antagonists against leptin receptor, gdf8 and activin a

Publications (1)

Publication Number Publication Date
MX2021007394A true MX2021007394A (es) 2021-07-15

Family

ID=69182653

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021007394A MX2021007394A (es) 2018-12-18 2019-12-17 Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
MX2026001345A MX2026001345A (es) 2018-12-18 2021-06-17 Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2026001345A MX2026001345A (es) 2018-12-18 2021-06-17 Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a

Country Status (10)

Country Link
US (1) US20240247071A2 (https=)
EP (1) EP3898672A1 (https=)
JP (1) JP7660507B2 (https=)
KR (1) KR20210104744A (https=)
CN (1) CN113195532B (https=)
AU (1) AU2019401575A1 (https=)
CA (1) CA3123024A1 (https=)
IL (1) IL283748A (https=)
MX (2) MX2021007394A (https=)
WO (1) WO2020131910A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3773713T (pt) 2018-04-06 2025-07-29 Regeneron Pharma Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
WO2024064842A1 (en) * 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
US20260000758A1 (en) * 2024-06-28 2026-01-01 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DK0690873T3 (da) 1993-03-19 2003-09-29 Univ Johns Hopkins Med Vækstdifferentieringsfaktor-8
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
HK1044159A1 (zh) 1998-12-01 2002-10-11 蛋白质设计实验室股份有限公司 抗γ-干扰素的人化抗体
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
AR047392A1 (es) 2002-10-22 2006-01-18 Wyeth Corp Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
ATE557042T1 (de) 2004-03-23 2012-05-15 Lilly Co Eli Anti-myostatin-antikörper
ES2463476T3 (es) 2004-10-19 2014-05-28 Regeneron Pharmaceuticals, Inc. Método para generar un ratón homocigótico para una modificación genética
US7307142B2 (en) 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
EP1877075A4 (en) 2005-04-25 2008-07-30 Pfizer ANTIBODY TO MYOSTATIN
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
EP1951756B1 (en) 2005-10-06 2015-01-07 Eli Lilly And Company Anti-myostatin antibodies
UA92504C2 (en) 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
BRPI0716249A2 (pt) 2006-09-05 2013-09-03 Lilly Co Eli anticorpos antimiostatina
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
UY32341A (es) 2008-12-19 2010-07-30 Glaxo Group Ltd Proteínas de unión antígeno novedosas
JO3340B1 (ar) * 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
DK2780368T3 (en) * 2011-11-14 2018-02-05 Regeneron Pharma COMPOSITIONS AND PROCEDURES FOR INCREASING MUSCLE MASS AND MUSCLE STRENGTH BY SPECIFIC ANTAGONIZATION OF GDF8 AND / OR ACTIVIN A
TW201920262A (zh) * 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
KR20170135967A (ko) * 2015-04-15 2017-12-08 리제너론 파마슈티칼스 인코포레이티드 Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
LT3538554T (lt) 2016-11-08 2025-10-10 Antigeną surišantys baltymai, antagonizuojantys leptino receptorius

Also Published As

Publication number Publication date
CN113195532B (zh) 2025-04-11
CN113195532A (zh) 2021-07-30
US20220220213A1 (en) 2022-07-14
MX2026001345A (es) 2026-03-02
AU2019401575A1 (en) 2021-06-17
WO2020131910A1 (en) 2020-06-25
JP2022512346A (ja) 2022-02-03
US20240247071A2 (en) 2024-07-25
IL283748A (en) 2021-07-29
EP3898672A1 (en) 2021-10-27
JP7660507B2 (ja) 2025-04-11
KR20210104744A (ko) 2021-08-25
CA3123024A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
GB2578539B (en) Compositions and methods for preventing or treating muscle conditions
MX2025003987A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos
MX2026001345A (es) Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a
ZA202007839B (en) Polymerases, compositions, and methods of use
ZA202007838B (en) Polymerases, compositions, and methods of use
PH12018501656A1 (en) Methods for using fxr agonists
ZA202101362B (en) Compositions and methods for treating the eye
GB202017595D0 (en) Compositions, and methods and uses relating thereto
GB201014026D0 (en) Treatment
SG10201900041VA (en) Meningococcus vaccines
GB201901099D0 (en) Methods, uses and compositions
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
IL266174A (en) Methods, compositions and dosage regimens for the treatment or prevention of interferon-gamma-related indications
ZA202101342B (en) Compositions and methods for treating the eye
MY208313A (en) Compositions and methods for treating brain injury
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
MX2021006102A (es) Suministro mejorado de agentes grandes.
MX2020013209A (es) Composiciones herbicidas.
EP3737355A4 (en) COMPOSITIONS AND METHODS OF TREATING A NERVE INJURY
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
MX2018000684A (es) Composiciones y metodos antitusivos.
ZA202101361B (en) Compositions and methods for treating the eye
IL288478B2 (en) Methods, compositions and devices for treating neuroinflammatory conditions
PH12019502145A1 (en) Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient
WO2020097079A8 (en) Methods for treating traumatic brain injury